EUVIMEDEUVIMED entdecken
Open Access

Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial

Kibrom B Girum, Anne-Ségolène Cottereau, Laetitia Vercellino, Louis Rebaud, Jérôme Clerc, Olivier Casasnovas, Franck Morschhauser, Catherine Thieblemont, Irène Buvat

Journal of Nuclear Medicine · 2024-02 · 65 (2) · 313-319

DOI: 10.2967/jnumed.123.266322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 07.12.2023. Verfasst von Kibrom B Girum und 8 weiteren Autor:innen. Beteiligte Einrichtung: LITO Laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, France. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Baseline [18F]FDG PET/CT radiomic features can improve the survival prediction in patients with diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to investigate whether characterizing tumor locations relative to the spleen location in baseline [18F]FDG PET/CT images predicts survival in patients with DLBCL and improves the predictive value of total metabolic tumor volume (TMTV) and age-adjusted international prognostic index (IPI).

Methods

This retrospective study included 301 DLBCL patients from the REMARC (NCT01122472) cohort. Physicians delineated the tumor regions, whereas the spleen was automatically segmented using an open-access artificial intelligence algorithm. We systematically measured the distance between the centroid of the spleen and all other lesions, defining the SD of these distances as the lesion spread (SpreadSpleen). We calculated the maximum distance between the spleen and another lesion (Dspleen) for each patient and normalized it with the body surface area, resulting in standardized Dspleen (sDspleen). The predictive value of each PET/CT feature for progression-free survival (PFS) and overall survival (OS) was evaluated through univariate and multivariate time-dependent Cox models and Kaplan-Meier analysis.

Results

In total, 282 patients (mean age, 68.33 ± 5.41 y; 164 men) were evaluated. The artificial intelligence algorithm successfully segmented the spleen in 96% of the patients. SpreadSpleen, Dspleen, and sDspleen were correlated neither with TMTV (Pearson ρ < 0.23) nor with IPI (Pearson ρ < 0.15). When median values were used as the cutoff, SpreadSpleen, Dspleen, and sDspleen all significantly classified patients into 2 risk groups for PFS and OS (P < 0.001). They complemented TMTV and IPI to classify the patients into 3 risk groups for PFS and OS (P < 0.001). Integrating SpreadSpleen, Dspleen, or sDspleen into a Cox model on the basis of TMTV, IPI, and TMTV combined with IPI significantly improved the concordance index for PFS and OS (P < 0.05).

Conclusion

Baseline PET/CT features that characterize tumor spread and dissemination relative to the spleen strongly predicted survival in patients with DLBCL. Integrating these features with TMTV and IPI further improved survival prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyLymphoma, Large B-Cell, DiffuseMaleHumansMiddle AgedAgedPrognosisSpleenFluorodeoxyglucose F18Retrospective StudiesArtificial IntelligenceTumor Burden

Stichwörter der Autor:innen

CTDLBCLFDGartificial intelligencetumor location

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • LITO Laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, France.
  • Department of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
  • Department of Nuclear Medicine, Saint Louis Hospital, AP-HP, Paris, France.
  • Research and Clinical Collaborations, Siemens Medical Solutions USA, Knoxville, Tennessee.
  • Department of Hematology, University Hospital of Dijon, Dijon, France.
  • Research Group on Injectable Forms and Associated Technologies, Department of Hematology, Claude Huriez Hospital, University Lille, Lille, France; and.

Zitieren

APA

Girum, K. B., Cottereau, A. S., Vercellino, L., Rebaud, L., Clerc, J., Casasnovas, O., Morschhauser, F., Thieblemont, C., & Buvat, I. (2024). Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial. Journal of Nuclear Medicine, 65(2), 313-319. https://doi.org/10.2967/jnumed.123.266322

Vancouver

Girum KB, Cottereau AS, Vercellino L, Rebaud L, Clerc J, Casasnovas O, et al. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial. Journal of Nuclear Medicine. 2024;65(2):313-319. doi:10.2967/jnumed.123.266322

BibTeX
@article{Girum2024,
  author = {Girum, Kibrom B and Cottereau, Anne-Ségolène and Vercellino, Laetitia and Rebaud, Louis and Clerc, Jérôme and Casasnovas, Olivier and Morschhauser, Franck and Thieblemont, Catherine and Buvat, Irène},
  title = {Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {2},
  pages = {313--319},
  doi = {10.2967/jnumed.123.266322}
}
Kostenlos starten →